PMC:7523471 / 84427-85742 JSONTXT

{"project":"TEST0","denotations":[{"id":"33041751-232-240-816871","span":{"begin":304,"end":308},"obj":"[\"28814675\"]"},{"id":"33041751-157-165-816872","span":{"begin":669,"end":673},"obj":"[\"28814675\"]"},{"id":"33041751-222-230-816873","span":{"begin":898,"end":902},"obj":"[\"28814675\"]"}],"text":"Importantly, in the proof-of-principal clinical trial, this noninvasive amyloid imaging technique revealed a significant 2.1-fold greater retinal amyloid burden, termed as retinal amyloid index (RAI), in a group of 10 AD patients as compared to 6 age-matched healthy controls (Figure 7E; Koronyo et al., 2017). Supported by histological findings, retinal Aβ deposits were often found the mid- and far-periphery of the superior and inferior regions, where previously NFL thinning was reported as more pronounced. Further, amyloid deposits were found above the retinal pigment epithelium in the neurosensory retina, unlike the typical location of drusen (Koronyo et al., 2017). Anecdotal data from 2 AMD patients suggested that retinal curcumin fluorescence signals were diffuse and concentrated at the posterior pole, apparently distinct from findings in the retinas of AD patients (Koronyo et al., 2017). Moreover, results presented at the Alzheimer’s Association International Conference on July 15, 2014, from a large cohort of over 150 MCI, AD, and cognitively normal participants of the Australian Imaging, Biomarker and Lifestyle (AIBL) Study (www.aibl.csiro.au) found that retinal amyloid fluorescence imaging predicted cerebral amyloid burden and was significantly higher in AD patients (Frost et al., 2014)."}

{"project":"2_test","denotations":[{"id":"33041751-28814675-38666657","span":{"begin":304,"end":308},"obj":"28814675"},{"id":"33041751-28814675-38666658","span":{"begin":669,"end":673},"obj":"28814675"},{"id":"33041751-28814675-38666659","span":{"begin":898,"end":902},"obj":"28814675"}],"text":"Importantly, in the proof-of-principal clinical trial, this noninvasive amyloid imaging technique revealed a significant 2.1-fold greater retinal amyloid burden, termed as retinal amyloid index (RAI), in a group of 10 AD patients as compared to 6 age-matched healthy controls (Figure 7E; Koronyo et al., 2017). Supported by histological findings, retinal Aβ deposits were often found the mid- and far-periphery of the superior and inferior regions, where previously NFL thinning was reported as more pronounced. Further, amyloid deposits were found above the retinal pigment epithelium in the neurosensory retina, unlike the typical location of drusen (Koronyo et al., 2017). Anecdotal data from 2 AMD patients suggested that retinal curcumin fluorescence signals were diffuse and concentrated at the posterior pole, apparently distinct from findings in the retinas of AD patients (Koronyo et al., 2017). Moreover, results presented at the Alzheimer’s Association International Conference on July 15, 2014, from a large cohort of over 150 MCI, AD, and cognitively normal participants of the Australian Imaging, Biomarker and Lifestyle (AIBL) Study (www.aibl.csiro.au) found that retinal amyloid fluorescence imaging predicted cerebral amyloid burden and was significantly higher in AD patients (Frost et al., 2014)."}

{"project":"0_colil","denotations":[{"id":"33041751-28814675-816871","span":{"begin":304,"end":308},"obj":"28814675"},{"id":"33041751-28814675-816872","span":{"begin":669,"end":673},"obj":"28814675"},{"id":"33041751-28814675-816873","span":{"begin":898,"end":902},"obj":"28814675"}],"text":"Importantly, in the proof-of-principal clinical trial, this noninvasive amyloid imaging technique revealed a significant 2.1-fold greater retinal amyloid burden, termed as retinal amyloid index (RAI), in a group of 10 AD patients as compared to 6 age-matched healthy controls (Figure 7E; Koronyo et al., 2017). Supported by histological findings, retinal Aβ deposits were often found the mid- and far-periphery of the superior and inferior regions, where previously NFL thinning was reported as more pronounced. Further, amyloid deposits were found above the retinal pigment epithelium in the neurosensory retina, unlike the typical location of drusen (Koronyo et al., 2017). Anecdotal data from 2 AMD patients suggested that retinal curcumin fluorescence signals were diffuse and concentrated at the posterior pole, apparently distinct from findings in the retinas of AD patients (Koronyo et al., 2017). Moreover, results presented at the Alzheimer’s Association International Conference on July 15, 2014, from a large cohort of over 150 MCI, AD, and cognitively normal participants of the Australian Imaging, Biomarker and Lifestyle (AIBL) Study (www.aibl.csiro.au) found that retinal amyloid fluorescence imaging predicted cerebral amyloid burden and was significantly higher in AD patients (Frost et al., 2014)."}